Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Myocardial Fibrosis Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Myocardial Fibrosis Overview | 8 | 1 |
| Pipeline Products for Myocardial Fibrosis Comparative Analysis | 9 | 1 |
| Myocardial Fibrosis Therapeutics under Development by Companies | 10 | 1 |
| Myocardial Fibrosis Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Myocardial Fibrosis Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Myocardial Fibrosis Products under Development by Companies | 14 | 1 |
| Myocardial Fibrosis Products under Investigation by Universities/Institutes | 15 | 1 |
| Myocardial Fibrosis Companies Involved in Therapeutics Development | 16 | 10 |
| AstraZeneca Plc | 16 | 1 |
| Evotec AG | 17 | 1 |
| Galectin Therapeutics, Inc. | 18 | 1 |
| GTx, Inc. | 19 | 1 |
| Invivosciences, Inc. | 20 | 1 |
| MandalMed, Inc. | 21 | 1 |
| miRagen Therapeutics, Inc. | 22 | 1 |
| Regulus Therapeutics Inc. | 23 | 1 |
| Shire Plc | 24 | 1 |
| TRACON Pharmaceuticals, Inc. | 25 | 1 |
| Myocardial Fibrosis Therapeutics Assessment | 26 | 9 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 26 |
| AZ-876 - Drug Profile | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| Drugs for Tissue Fibrosis - Drug Profile | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| GM-CT-01 - Drug Profile | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 3 |
| GRMD-02 - Drug Profile | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 3 |
| GTx-878 - Drug Profile | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| MGN-4220 - Drug Profile | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 1 |
| Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 1 |
| NM-922 - Drug Profile | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 1 |
| Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 2 |
| RG-012 - Drug Profile | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| R&D Progress | 49 | 3 |
| SHP-627 - Drug Profile | 52 | 1 |
| Product Description | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| R&D Progress | 52 | 1 |
| Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis - Drug Profile | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 1 |
| SP-20102 - Drug Profile | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 1 |
| TPI-2049 - Drug Profile | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| TRC-105 - Drug Profile | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 4 |
| TRC-205 - Drug Profile | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 1 |
| Myocardial Fibrosis Recent Pipeline Updates | 61 | 18 |
| Myocardial Fibrosis - Dormant Projects | 79 | 1 |
| Myocardial Fibrosis Product Development Milestones | 80 | 1 |
| Featured News &Press Releases | 80 | 1 |
| Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter | 80 | 1 |
| Appendix | 81 | 2 |
| Methodology | 81 | 1 |
| Coverage | 81 | 1 |
| Secondary Research | 81 | 1 |
| Primary Research | 81 | 1 |
| Expert Panel Validation | 81 | 1 |
| Contact Us | 81 | 1 |
| Disclaimer | 82 | 1 |